share_log

康希諾生物：海外監管公告

CANSINOBIO: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 30 09:09
Summary by Moomoo AI
康希諾生物於2023年年度報告中披露，公司實現營業收入3.57億元，同比減少65.49%，歸母淨虧損14.83億元，同比增虧63.04%，主營業務毛利率為26.50%，新冠疫苗產品銷售收入下降96.86%。公司根據新冠疫苗的實際及預期退貨情況，核算冲減收入2.53億元。此外，公司應收賬款餘額合計6.63億元，其中1年以上的應收賬款占比達27.80%，2022年對應占比為0.67%。公司解釋，新冠疫苗相關應收賬款回收較慢，導致1年以上應收賬款占比增加。至於公司的資金情況，2023年末公司貨幣資金及交易性金融資產合計約41.30億元，短期借款及長期借款合計約19.20億元。公司進行了外匯套期保值業務，以管理金融資產的匯率風險，並於報告期內實現收益1,569.10萬元。
康希諾生物於2023年年度報告中披露，公司實現營業收入3.57億元，同比減少65.49%，歸母淨虧損14.83億元，同比增虧63.04%，主營業務毛利率為26.50%，新冠疫苗產品銷售收入下降96.86%。公司根據新冠疫苗的實際及預期退貨情況，核算冲減收入2.53億元。此外，公司應收賬款餘額合計6.63億元，其中1年以上的應收賬款占比達27.80%，2022年對應占比為0.67%。公司解釋，新冠疫苗相關應收賬款回收較慢，導致1年以上應收賬款占比增加。至於公司的資金情況，2023年末公司貨幣資金及交易性金融資產合計約41.30億元，短期借款及長期借款合計約19.20億元。公司進行了外匯套期保值業務，以管理金融資產的匯率風險，並於報告期內實現收益1,569.10萬元。
DISCLOSED IN ITS 2023 ANNUAL REPORT, CONXINO BIO ACHIEVED OPERATING REVENUE OF $3.57 MILLION, DOWN 65.49% YEAR-ON-YEAR, NET MATERNITY LOSS OF $14.83 BILLION, A YEAR-ON-YEAR LOSS OF 63.04%, GROSS MARGIN FROM PRIMARY BUSINESS WAS 26.50%, AND SALES REVENUE FOR CORONAVIRUS PRODUCTS DECREASED 96.86%. Based on the actual and expected return of the COVID-19 vaccine, the company reported a revenue reduction of $2.53 million. In addition, the company's balance of accounts receivable totaled $6.63 billion, of which 27.80% of accounts receivable for more than 1 year and 0.67% in 2022, respectively. The company explained that the recovery of receivables related to the COVID-19 vaccine was slower, resulting in an increase in the proportion of receivables for more than 1 year. As for the capital situation of the company, the company...Show More
DISCLOSED IN ITS 2023 ANNUAL REPORT, CONXINO BIO ACHIEVED OPERATING REVENUE OF $3.57 MILLION, DOWN 65.49% YEAR-ON-YEAR, NET MATERNITY LOSS OF $14.83 BILLION, A YEAR-ON-YEAR LOSS OF 63.04%, GROSS MARGIN FROM PRIMARY BUSINESS WAS 26.50%, AND SALES REVENUE FOR CORONAVIRUS PRODUCTS DECREASED 96.86%. Based on the actual and expected return of the COVID-19 vaccine, the company reported a revenue reduction of $2.53 million. In addition, the company's balance of accounts receivable totaled $6.63 billion, of which 27.80% of accounts receivable for more than 1 year and 0.67% in 2022, respectively. The company explained that the recovery of receivables related to the COVID-19 vaccine was slower, resulting in an increase in the proportion of receivables for more than 1 year. As for the capital situation of the company, the company's monetary capital and transactional financial assets at the end of 2023 amounted to about $41.30 million, and short-term borrowings and long-term loans totaled about $19.20 billion. The company conducted a foreign exchange hedging business to manage the exchange rate risk of financial assets and achieved revenues of $1,569.10 million during the reporting period.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more